A multi-center study of 30 high-risk patients transplanted for multiple myeloma has demonstrated 18-month overall survival of 78% for patients who received post-transplant lenalidomide maintenance therapy. Median age of transplant recipients was 54 years (range 38-68), and the median time from transplant to lenalidomide initiation was 96 days (range 66-171). Maintenance lenalidomide was given daily on days 1-21 of a 28-day cycle, and 10 mg daily was the most commonly delivered dose (44%). Eleven patients (37%) completed maintenance; the most common reasons for discontinuation were acute GVHD (37%) and disease progression (37%). Progression-free survival at 18 months was 63%.
Lenalidomide Maintenance after HCT for High-Risk Multiple Myeloma